Although gemistocytic astrocytomas are graded as World Health Organization II astrocytomas, they behave more aggressively. Their proliferative potential is low and it remains an intriguing question why these tumors are so biologically "successful." They show a high mutation rate of the P53 gene, cytological abnormalities, and frequent perivascular mononuclear infiltrates. Microglial cells, a feature of this astrocytoma variant, are of increasing interest in the context of glioma growth. METHODS: We selected 23 tumor biopsies from 201 samples obtained from patients with gemistocytic astrocytomas operated at Mayo Clinic between 1985 and 1998. These tumors were formerly analyzed for P53 mutations, p53 protein, and proliferative activity (9). Immunolabeling for three microglial markers, including CR3/43, Ki-M1P, and iba1, was performed on adjacent tissue sections. In addition, in situ hybridization for the α-chain of the major histocompatibility complex (MHC) Class II molecule recognized by the CR3/43 monoclonal antibody was performed. RESULTS: A high number of microglia was detected in gemistocytic astrocytomas. More microglia were present if the fraction of gemistocytic tumor cells was high (correlation coefficient ϭ 0.699; P Ͻ 0.0002). Interestingly, a number of gemistocytes were immunoreactive for MHC Class II molecules, an observation confirmed by in situ hybridization. Importantly, the higher the number of Class II immunoreactive gemistocytes, the fewer Class II positive microglial cells could be detected (correlation coefficient ϭ Ϫ0.5649; P Ͻ 0.005). CONCLUSION: Our results support the view that gemistocytic astrocytomas contain unusually high numbers of microglial cells. We propose that the finding of aberrant MHC Class II expression by gemistocytic tumor cells correlates with a loss of immunecompetent MHC Class II-expressing microglia. This may be related to the especially poor prognosis of gemistocytic astrocytomas for which induction of T cell anergy could provide one explanation.
G
emistocytic astrocytomas represent a distinct histological subtype of diffuse astrocytoma. These are classified as World Health Organization (WHO) Grade II astrocytomas but behave more aggressively than other diffuse astrocytoma variants (8) . Accordingly, the presence of a large fraction of gemistocytic tumor cells (Ͼ20%) in diffuse astrocytomas is regarded as a sign of poor prognosis, and the majority of gemistocytic astrocytomas progress rapidly to anaplastic astrocytoma (WHO Grade III) or glioblastoma (WHO Grade IV) (20) .
Nissl first described gemistocytes as gemästete glia (flattened glia) in 1904. The Greek gemisto ("filled, stuffed") gave rise to the English term gemistocytic. Reactive astrocytes can also have a gemistocytic appearance, especially in subacute infarction and acute demyelination. In general, gemistocytes have abundant, homogenous, and eosinophilic cytoplasm. They often have an eccentric nucleus, even in their nonneoplastic form. It is nuclear atypia that distinguishes nonneoplastic from neoplastic gemistocytes (19) .
Previous studies have shown that gemistocytic astrocytoma cells are mainly in the nondividing, G 0 phase of the cell cycle (19) . Accordingly, neoplastic gemistocytic astrocytomas show surprisingly low proliferative activity, as can be demonstrated by bromodeoxyuridine incorporation (16) , or by immunolabeling with the monoclonal proliferation marker, MIB-1 (24) . Importantly, gemistocytic astrocytomas are characterized by a high mutation rate of the P53 gene (9, 24) , high expression of the anti-apoptotic substance, bcl-2 (24) , and frequent perivascular mononuclear infiltrates (22) . Gemistocytic astrocytes in both their non-neoplastic and neoplastic form show strong glial fibrillary acidic protein immunoreactivity.
Penfield (17) was probably the first to give a detailed description of microglia in gliomas. In recent years, it has become clear that microglia are resident brain macrophage precursor cells and that they form a network of immune-competent cells within the normal central nervous system. A number of studies have demonstrated that there are surprisingly high numbers of microglia/macrophages in gliomas (14, 25) . Herein, we studied microglia in a well-characterized series of gemistocytic astrocytomas and examined their potential to engage in antigen presentation based on their expression of major histocompatibility complex (MHC) Class II antigens. Both immunocytochemistry and in situ hybridization (ISH) were used.
MATERIALS AND METHODS

Case Selection
We selected 23 tumor samples from among 201 samples obtained from patients with gemistocytic astrocytomas operated at Mayo Clinic between 1985 and 1998. All tumors were selected and classified based on current WHO criteria (7) . The tumor samples were selected by the same two observers (BWS, MBG) based on a "typical appearance" in standard hematoxylin and eosin-stained paraffin sections.
Additional information is available online (www.ICDNS. org). Grade II tumors of this study were diffusely infiltrative and composed of astrocytic cells showing nuclear atypia (nucleomegaly, hyperchromasia, and pleomorphism). They had none or only a solitary mitosis. Endothelial proliferation and necrosis were lacking. The percentage of full-bodied tumor cells with abundant eccentric pink cytoplasm ("gemistocytic astrocytoma cells") was at least 20% in all cases.
Grade III gemistocytic tumors also showed diffuse infiltrative behavior and were composed of astrocytic cells displaying comparable or greater nuclear atypia (nucleomegaly, hyperchromasia, and pleomorphism) than Grade II tumors, and increased mitotic activity. Grade IV tumors were diffusely infiltrative tumors composed of astrocytic cells featuring nuclear atypia (nucleomegaly, hyperchromasia, and pleomorphism), mitotic activity, and either or both endothelial proliferation or necrosis with or without palisading. These tumors varied in cytology. "Gliosarcomas" were not included in the present study.
The tumors examined in this study were previously analyzed for P53 mutations, p53 protein, and proliferative activity (9) . The design for this study was approved by the institutional ethics review board of Mayo Clinic Rochester. Table 1 shows the characteristics of each case on the basis of age, sex, WHO grade, location of the tumor, and patient survival (in mo) after surgery. In total, there were six (26.09%), 12 (52.17%), and five (21.74%) gemistocytic tumors of WHO Grades II, III, and IV, respectively. Of the samples studied, 16 (69.57%) tumors were from men and seven (30.43%) were from women aged 21 to 78 years (mean Ϯ 2 standard deviations, 39.65 Ϯ 15.06 yr). Only five patients were alive at the time of follow-up, a reflection of the aggressive nature of this tumor. Case GA20 had a limited (9 mo) follow-up period, this being the value used in the survival calculations as the minimum survival.
Immunocytochemistry
Immunolabeling for three established microglia markers, including CR3/43, Ki-M1P, and iba1, was performed on adjacent tissue sections using standard methods (23) . The CR3/43 monoclonal antibody recognizes the β-chain of human lymphocyte antigen (HLA)-D related (DR), DP, and DQ. Ki-M1P recognizes CD68 (18) . Iba1 binds to fimbrin and is a wellestablished microglia marker (15) . CR3/43 is perhaps the best marker for "activated" human microglia that works on paraffin sections. We have previously reported on its specificity in nonneoplastic central nervous system tissue (5). Representative tissue areas were chosen on the basis of hematoxylin and eosin-stained sections and verified using immunohistochemistry. Digital images were taken at 150-bit resolution using a Zeiss Axipophot microscope (Carl Zeiss, Göttingen, Germany) with a ϫ40 objective connected to a Practica color scanner (Practica, Dresden, Germany). The number of labeled microglia and gemistocytic astrocytoma cells, as well as the total number of nuclei, were determined in one large representative visual field per case by two different researchers and were documented by digital photography. The tissue area photographed and used for counting was 0.19 mm 2 for all markers tested.
The gemistocyte index (GI) for this study was recalculated for the sampled tissue areas of the CR3/43-immunolabeled sections (i.e., it was adjusted and is, therefore, denoted, GIa). It represents the density of these cells in the given section (total number of gemistocytes divided by the total number of nuclei). GI+ denotes the MHC Class II GI (i.e., the total number of Class II gemistocytes divided by the total number of gemistocytes). The microglial index (MI) represents the total number of microglia divided by the total number of nuclei in each field, and was calculated for each case using all three immunolabeled sections (CR3/43, Ki-1MP, and iba1).
Radioactive ISH for MHC Class II Expression by Microglia and Gemistocytes
Characteristics of the Deoxyribonucleic Acid Sequence Identified for ISH
A 306-bp-long polymerase chain reaction (PCR) fragment was amplified from the plasmid pDR-α-I containing the fulllength HLA-DRA complementary deoxyribonucleic acid sequence isolated from Raji cells (10) . The amplified fragment corresponds to the part of the 3տ untranslated region between nucleotides 717 and 1006 in the original sequence. The PCR reaction was performed with the forward primer 5տ-TGGTGGATCCGATGGTGTTTCTTAGAGAGA-3տ and the reverse primer 5տ-ATGAGGATCCGGGCATTCCATAGCA-GAGAC-3տ. The fragment was cloned into the BamHI site of the phagemid pT7T3 18U (Pharmacia LKB, Uppsala, Sweden) to allow in vitro transcription of the insert in both directions. The construct was verified by restriction enzyme cleavage and nucleotide sequencing. The HLA-DRA fragment was inserted in the vector so that the T3 promoter can be used for transcription in the sense direction and the T7 promoter can be used for transcription in the antisense direction.
Ribonucleic Acid Probe Preparation
Two nanograms of the plasmid containing the HLA-DRA fragment were amplified via PCR with primers specific for the T7/T3 site of the vector (T3: CGAAATTAACCCTCAC-TAAAG; T7: TAATACGACTCACTATAGGG). PCR conditions were as followed: 25 cycles with denaturation at 92ЊC for 10 seconds, primer annealing at 53ЊC for 20 seconds, and elongation at 74ЊC for 40 seconds. The PCR product was purified from primers and salt with the QuiaQuick-kit (Quiagen, Hilden, Germany). For in vitro transcription, 250 ng of the purified PCR product was incubated with T7 polymerase for the antisense probe and 60 µCi of 35 S-dUTP (Amersham Pharmacia, Freiburg, Germany) at 37ЊC for 2 hours, according to the manufacturer 's instructions (Roche Boehringer Mannheim, Mannheim, Germany). The quality of incorporation of 35 S-dUTP was controlled by polyacrylamide gel electrophoresis. Transcription with T3-polymerase was performed for the generation of the sense probe, which served as the negative control.
Hybridization
Paraffin-embedded sections were deparaffinized in xylene, rehydrated in an ethanol series of descending concentration, fixed in 4% phosphate-buffered formalin for 20 minutes, and washed in 0.1 mol/L phosphate-buffered saline. This was followed by treatment of the sections with 5 µg/ml proteinase K (Roche Boehringer Mannheim) for 10 minutes at 37ЊC, refixation in 4% formalin, and washing. Sections were then acetylated for 10 minutes in 0.25% acetic acid anhydride solution (0.25% acetic acid anhydride and 0.1 mol/L triethanolamineHCl), washed, dehydrated in an ascending ethanol series, and air dried. For hybridization, 2 ϫ 10 6 cpm of the labeled ribonucleic acid (RNA) probe was diluted in a buffer consisting of 50% formamide, 20 mmol/L Tris-HCl, 5 mmol/L EDTA (pH 8), 10 mmol/L phosphate buffer, 1X Denhardts, 10% dextran sulfate, 0.2% Sarcosyl solution, 500 µg/ml transfer RNA, and 200 µg/ml single-stranded salmon sperm deoxyribonucleic acid. Before overnight incubation of the buffered probe at 55ϯC, sections were incubated with the hybridization buffer alone for 60 minutes. The following day, sections were washed with increasing stringency (decreasing concentration of standard sodium citrate) and incubated in 1 µg/ml RNAse (Roche Boehringer Mannheim) for 30 minutes. Dehydrated sections were covered with NTB2 film emulsion (Kodak, Rochester, NY), exposed at 4ЊC for 14 days, developed with Kodak D-19 developer, and counterstained with erythrosin and hemalum (21, 26) .
Statistical Methods
Means, standard deviations, and frequencies were used to describe the cohort. Because several of the variables were skewed, Spearman's rank correlation was used to assess the association between factors. All tests were two-sided, with a P value of less than 0.05 considered statistically significant. Linear regression analysis using Sigmastat 2.03 (SPSS, Inc., Chicago, IL) was additionally used to describe the immunohistochemical parameters. The Cox proportional hazards model was used to assess patient survival. Table 2 shows the quantitative analysis from which the following results are derived. The mean and standard deviations of GIa, GI+, and MI CR3/43 were 0.27 Ϯ 0.13, 0.47 Ϯ 0.36, and 0.19 Ϯ 0.12, respectively. Nine out of 23 sections studied exhibited less than 20% gemistocytes. However, of these, seven had been found to have more than 20% gemistocytes in the adjacent tissue sections (9) . This was thought to be caused by hypodensity of gemistocytes in this particular section rather than being representative of the tumor in general. 
RESULTS
More Microglial Cells Are Found in Tumors Containing Large Numbers of Gemistocytes
Gemistocytic Astrocytomas Containing Large Numbers of MHC Class II-Expressing Gemistocytes Show Reduced Numbers of Microglial Cells
There was a negative correlation between the microglia and the Class II gemistocyte indices (number of cases, 23; correlation coefficient, Ϫ0.5649; P Ͻ 0.005) as illustrated by Figure 2B . 
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ISH
ISH revealed that not only microglial cells, but also fullbodied gemistocytes showed intense silver labeling over their cytoplasm, indicating the presence of the message for the MHC Class II α-chain molecule. This supported our findings based on CR3/43 monoclonal antibody staining (Figs. 1B and 1C,  respectively) . Table 3 demonstrates the results of the Cox proportional hazards model assessing survival. This method yields an estimated hazard ratio for the factor of interest. For example, the hazard ratio for sex (male versus female) is 1.36, indicating that men are at 36% higher risk of death than women at any time during their follow-up. A hazard ratio of 1.0 would indicate no increased risk, whereas a ratio less than 1 indicates decreased risk in the presence of that factor. For continuous factors, the hazard ratio indicates the increased risk with each one-unit change in the factor.
Survival Analysis
As expected, the WHO grade was a statistically significant predictor of death. Increase in MI as shown by iba 1, CR3/43, and Ki-M1P, was shown to decrease the risk of death, although this was only significant with respect to the former (P ϭ 0.0271). There was only a small (2.5%) statistically insignificant increase in risk of death for each additional year of age. The GI, GI+, and sex did not show a significant effect on survival.
MI Indices Had a Negative Correlation with P53 Labeling Index and P53 Gene Mutation Status in the Adjacent Tissue Sections
Twenty out of the 23 cases studied in this series had been previously analyzed for p53 labeling and P53 gene mutation (9) . In the previous study, the p53 index showed a negative correlation with the MI as labeled by iba1 (correlation coefficient, Ϫ0.5068; P Ͻ 0.02), and a negative correlation trend with Ki-M1P (correlation coefficient, Ϫ0.4346; P Ͻ 0.05), and CR3/43, although the latter did not reach statistical significance (correlation coefficient, Ϫ0.2481; P Ͻ 0.3). Thus, one could argue that the more p53 was expressed in the adjacent tissue sections, the fewer microglia were found.
Using a two-sample rank-sum test, the mean MI CR3/43 and MI Ki-M1P was higher in those without P53 gene mutation status (0.25 and 0.31, respectively) than in those with a P53 mutation status (0.13 and 0.20, respectively) (P Ͻ 0.05). Thus, those tumors with a P53 mutation had fewer microglia.
MI Iba1 Had a Negative Correlation with MIB Labeling Index
MI iba1 , but not the MI CR3/43 and MI ki-M1P , had a negative correlation (correlation coefficient, Ϫ0.5188; P Ͻ 0.02) with the MIB labeling index in the adjacent sections as determined in the previous study (9) , i.e., the more microglia, the less MIB labeling was observed in the adjacent tissue section. Figure 1 , D and F show the iba1 and MIB labeling of Case GA17.
There were no other correlations among the variables stated in Tables 1 and 2 . In addition, terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick endlabeling was essentially negative for all cases (data not shown). NEU179084 3 tables, 1 B&W fig., 1 4/C fig. 10 
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DISCUSSION
Gemistocytic Astrocytomas Contain Large Numbers of Microglial Cells
Our findings support the view that gemistocytic astrocytomas contain unusually high numbers of microglial cells. In fact, the results of several published studies indicate that approximately one-third of all cells in glioma biopsies label with macrophage markers (14) . In our personal experience, this percentage may be even higher, especially in anaplastic tumors wherein estimates exceed 50% of the total tumor mass. One published study has noted that gemistocytic astrocytomas contain high numbers of ramified microglia with long perpendicular branching processes (25) .
Although this case series had a relatively small number of cases, it is important to note that the significance of the findings are statistically powerful. However, to our surprise, there was only a small (2.5%) statistically insignificant increase in risk of death for each additional year of age. This may have been caused by a skew based on 47-and 58-year-old patients, who had 222-and 202-month survivals, respectively, and were alive at the time of the follow-up. It is clear, however, that these data are open to interpretation as long as the case numbers are relatively small and no large histologically uniform group can be selected.
Possible Immunological Implications of Aberrant MHC Class Expression by Tumor Cells and Microglial Class II Deregulation
Our results shed new light on the immunology of gemistocytic astrocytomas. We demonstrate that gemistocytic tumor cells express aberrant MHC Class II, and that this expression correlates with a reduction in MHC Class II-expressing microglia from the same tumor areas (i.e., a reduced potential for immune defense against tumor infiltration and growth). We cannot currently propose a specific mechanism that may underlie this correlation. One possible consequence of aberrant Class II expression can be the induction of T-cell anergy. A previous study using transgenic pancreatic islet β cells expressing MHC Class II molecules suggested that expression of MHC Class II on nonlymphoid cells may serve as an extrathymic mechanism for maintaining self tolerance (12) . Furthermore, Marelli-Berg and Lechler (11) proposed an important role for antigen presentation by parenchymal cells in the induction and the maintenance of peripheral tolerance. Recently, it has been shown that expression of MHC Class II by melanocytic tumor cells is positively correlated with the presence of tumorinfiltrating lymphocytes, regression of the lesion, decreased time to progression, and increased overall survival of the patients (1). However, it seems possible that immunological conditions in glioma are different. Studies are now necessary to ascertain the status of T-cell infiltrates and of the different lymphocyte subsets in gemistocytic tumors to determine whether or not those tumors that show rapid growth despite massive lymphocytic infiltration have a particularly high MHC Class II GI and whether or not they carry a different prognosis. We have also demonstrated that the more intense p53 and MIB labeling in the tissue sections, the fewer microglia were found, and tumors that exhibited a P53 mutation harbored fewer microglia.
Toward a New Gene Therapeutic Approach to Treat Astrocytoma by Using Microglia as a Trojan Horse?
It is important to note that brain macrophages can have different sources. The two main sources are 1) resident microglia that are intrinsic to the central nervous system parenchyma and 2) recently blood-derived monocyte/macrophages (4). Unequivocal evidence that parenchymal microglia can derive from bone-marrow precursors in the adult has been provided by bone marrow chimera experiments using a non-expressed marker gene, in which it was shown that microglia undergo a limited turnover with recently bone marrow-derived cells, even under conditions wherein the blood-brain barrier remains intact (2) .
The close association of the MHC Class II-positive microglia cells and tumor cell bodies, as also observed in this study, and, in particular, the fact that microglia are renewed from the bone marrow, lend strong support to the idea that microglia could be used as a natural vehicle, literally a Trojan horse (4), for the delivery of gene therapy to gliomas. Our laboratory has started to explore this possibility.
Indeed, the microglial capacity for antigen presentation could be exploited for a new approach to the immune therapy of astrocytoma. However, in recent years, it has become clear that the immune function of microglia is reduced in these tumors (3) . The ability of the microglia to function as professional antigen presenters seems especially compromised in malignant gliomas. We have shown previously that, in other astrocytoma subtypes, the number of MHC Class II-expressing microglia decreases with higher tumor grade. As in the present study, tumor cells were found to bind MHC Class II antibody (23) . It has also been demonstrated that glioma-infiltrating microglia are not capable of secreting key cytokines (6) . Perhaps microglia genetically engineered and supplied freshly via the blood stream would be less compromised and could form part of a new therapeutic strategy to eliminate diffusely growing astrocytoma cells, which are otherwise inaccessible.
The role of inflammatory tissue changes in relation to promotion of tumor growth is also under scrutiny. Inflammation as a mechanism supporting tumor progression has been implicated in other tumors, such as liver cancers, but its key molecular machinery remains ill-defined. Recently NF-κ B, an inflammation-induced protein has been suggested as a key player in tumorigenesis. It is thought that involvement of NF-κB could lead to changes promoting formation of proinflammatory chemicals, such as colony stimulating factor 1 and cyclooxygenase 2, which themselves give a further boost to the inflammatory process (13) .
CONCLUSION
We propose that the findings reported herein may help explain the especially poor prognosis of gemistocytic astrocytomas. It is well known that the proliferative potential of neoplastic gemistocytes is low and it has remained an intriguing question why these tumors are so biologically "successful." Aberrant expression of MHC Class II molecules by nonprofessional antigen presenters (i.e., gemistocytic tumor cells) might induce T-cell anergy, providing one possible explanation. We are aware that this concept requires additional support from both case work and experimental studies. Specifically, the role of MHC Class II-restricted CD4 T cells in astrocytoma immunity will have to be scrutinized as one of the next steps. 
